Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience

Joana Desterro; Donal P. McLornan; Natalia Curto Garcia; Jennifer O'Sullivan; Samah Alimam; Clodagh Keohane; Claire Woodley; Yvonne Francis; Shahram Kordasti; Deepti H. Radia; Claire N. Harrison

doi:10.1111/bjh.15968

Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience

Joana Desterro, Donal P. McLornan, Natalia Curto Garcia, Jennifer O'Sullivan, Samah Alimam, Clodagh Keohane, Claire Woodley, Yvonne Francis, Shahram Kordasti, Deepti H. Radia, Claire N. Harrison^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the ‘real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.

Original language	English
Pages (from-to)	561-564
Number of pages	4
Journal	British Journal of Haematology
Volume	186
Issue number	4
Early online date	15 May 2019
DOIs	https://doi.org/10.1111/bjh.15968
Publication status	E-pub ahead of print - 15 May 2019

Keywords

cytoreduction
essential thrombocythaemia
interferon
myeloproliferative disorder
therapy
thrombosis

Access to Document

10.1111/bjh.15968

Cite this

Desterro, J., McLornan, D. P., Curto Garcia, N., O'Sullivan, J., Alimam, S., Keohane, C., Woodley, C., Francis, Y., Kordasti, S., Radia, D. H., & Harrison, C. N. (2019). Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience. British Journal of Haematology, 186(4), 561-564. Advance online publication. https://doi.org/10.1111/bjh.15968

@article{c8ecf0e7d3b4407d87ee0e0c4d839e04,

title = "Essential thrombocythaemia treated with recombinant interferon: {\textquoteleft}real world' United Kingdom referral centre experience",

abstract = "Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the {\textquoteleft}real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.",

keywords = "cytoreduction, essential thrombocythaemia, interferon, myeloproliferative disorder, therapy, thrombosis",

author = "Joana Desterro and McLornan, {Donal P.} and {Curto Garcia}, Natalia and Jennifer O'Sullivan and Samah Alimam and Clodagh Keohane and Claire Woodley and Yvonne Francis and Shahram Kordasti and Radia, {Deepti H.} and Harrison, {Claire N.}",

year = "2019",

month = may,

day = "15",

doi = "10.1111/bjh.15968",

language = "English",

volume = "186",

pages = "561--564",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Essential thrombocythaemia treated with recombinant interferon

T2 - ‘real world' United Kingdom referral centre experience

AU - Desterro, Joana

AU - McLornan, Donal P.

AU - Curto Garcia, Natalia

AU - O'Sullivan, Jennifer

AU - Alimam, Samah

AU - Keohane, Clodagh

AU - Woodley, Claire

AU - Francis, Yvonne

AU - Kordasti, Shahram

AU - Radia, Deepti H.

AU - Harrison, Claire N.

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the ‘real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.

AB - Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the ‘real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.

KW - cytoreduction

KW - essential thrombocythaemia

KW - interferon

KW - myeloproliferative disorder

KW - therapy

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85065968196&partnerID=8YFLogxK

U2 - 10.1111/bjh.15968

DO - 10.1111/bjh.15968

M3 - Article

AN - SCOPUS:85065968196

SN - 0007-1048

VL - 186

SP - 561

EP - 564

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this